ENSTILAR Drug Patent Profile

Which patents cover Enstilar, and when can generic versions of Enstilar launch?

Enstilar is a drug marketed by Leo Pharma As and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-six patent family members in twenty-five countries.

The generic ingredient in ENSTILAR is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.

DrugPatentWatch^® Generic Entry Outlook for Enstilar

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ENSTILAR

International Patents:	36
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ENSTILAR

Paragraph IV (Patent) Challenges for ENSTILAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ENSTILAR	Topical Foam	betamethasone dipropionate; calcipotriene	0.005%/0.064%	207589	1	2020-06-22

US Patents and Regulatory Information for ENSTILAR

ENSTILAR is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589-001	Oct 16, 2015		RX	Yes	Yes	10,688,108
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589-001	Oct 16, 2015		RX	Yes	Yes	9,119,781*PED				Y
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589-001	Oct 16, 2015		RX	Yes	Yes	10,617,698		Y
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589-001	Oct 16, 2015		RX	Yes	Yes	10,130,640*PED				Y
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589-001	Oct 16, 2015		RX	Yes	Yes	10,660,908		Y

International Patents for ENSTILAR

When does loss-of-exclusivity occur for ENSTILAR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

New Zealand

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ENSTILAR around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1182321	含有維生素 類似物和皮質類固醇的藥用噴霧劑組合物 (A PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN ANALOGUE AND A CORTICOSTEROID)
Israel	222865
South Korea	101619077
European Patent Office	2859886	Composition pharmaceutique pulverisable (A pharmaceutical spray composition)
Spain	2432691

ENSTILAR: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Enstilar (calcipotriol and betamethasone dipropionate) is a topical treatment primarily used for psoriasis management. Developed by LEO Pharma, it has secured FDA and EMA approvals, establishing a solid foothold in the dermatology market. This report analyzes Enstilar’s current market position, growth prospects, competitive landscape, investment considerations, and potential financial trajectories.

---

1. Market Overview and Dynamics

1.1 Psoriasis Market Size and Growth

• Global psoriasis market valuation: Estimated at USD 4.4 billion in 2022, expected to grow at a CAGR of 8.5% (2023–2030) [1].
• Key drivers:
  • Increasing prevalence: Approximately 2–3% of the global population affected [2].
  • Rising awareness and diagnosis.
  • Advancements in topical and systemic therapies.

1.2 Topical Psoriasis Treatments

Treatment Type	Market Share (2022)	Key Players	Notable Features
Corticosteroids	40%	Various; including Enstilar	First-line, broad acceptance
Vitamin D analogs	25%	Calcipotriol, Calcitriol	Often combined with corticosteroids
Combination products	20%	Enstilar, Taclonex	Synergistic efficacy, ease of use
Systemic & Biologic	15%	Humira, Cosentyx	Used for moderate to severe cases

1.3 Market Position of Enstilar

• Approved indications: Psoriasis vulgaris, scalp psoriasis.
• Differentiation: Once-daily topical foam with enhanced penetration, combining calcipotriol and betamethasone.
• Market penetration (2022): Estimated to hold 15–20% share of topical corticosteroid/vitamin D combination segment [3].

---

2. Investment Scenario Analysis

2.1 Current Revenue and Licensing

Metric	2022	Notes
Estimated global sales	USD 250–300 million	Based on market share and regional penetration
Major markets	North America, Europe, Asia	North America: USD 120M; Europe: USD 80M; Asia: USD 50M
Revenue growth (2020–2022)	Approx. 10% CAGR	Driven by strategic expansion and increased dermatology awareness

2.2 Growth Drivers

Drivers	Impact
New regional launches (e.g., Latin America, Africa)	Diversifies revenue base
Expanding indications to pediatric or other dermatological conditions	Increases market scope
Enhancement of formulation (e.g., steroid-free variants)	Addresses unmet needs, broadening patient access
Strategic acquisitions/licensing agreements	Accelerates market penetration and product portfolio expansion

2.3 Risks and Challenges

Risk Factors	Impact	Mitigation Strategies
Competition from generics	Price erosion, margin compression	Patent protections, lifecycle management strategies
Regulatory hurdles	Delays in launches, expanded indications	Robust regulatory strategy, dossier quality
Market saturation	Slower sales growth	Geographic expansion, product innovation
Pricing pressures in mature markets	Reduced profitability	Value-based pricing approaches

---

3. Competitive Landscape and Market Share

Competitor	Product/Brand	Key Features	Estimated Market Share (2022)	Strengths
Eli Lilly	Taclonex (calcipotriol + betamethasone)	Similar formulation, approved in US and EU	10–15%	Established presence, multi-regional access
Dermavant	Vtama (tapinarof)	New, steroid-free topical	~5%	Innovative, steroid-free alternative
Sandoz (Novartis)	Generic formulations	Price competitiveness	15% (general corticosteroid segment)	Cost advantage, wide distribution

---

4. Financial Trajectory Projections

4.1 Revenue Forecast (2023–2030)

Year	Estimated Sales (USD Million)	Assumptions
2023	300	Baseline + regional expansion
2024	330	New indications, increased market outreach
2025	370	Greater penetration, reduced generic competition
2026–2030	CAGR of 8.5%	Sustained market growth, lifecycle management

4.2 Profitability Outlook

Metrics	2022 Actual	Projections 2023–2030	Notes
Gross Profit Margin	~65%	66–68%	Cost efficiencies, pricing power
Operating Margin	~30%	32–35%	R&D investments, marketing expenses
Net Profit Margin	~20%	22–25%	Improved efficiencies, lifecycle value

---

5. Investment Considerations

Aspect	Evaluation
Market Position	Strong, with clear differentiation and growth potential
Patent & IP Status	Patent expiry estimated 2027; lifecycle management crucial
Regulatory Environment	Generally supportive, but with regional variations
Competitive Threat	Generics and new formulations could challenge market share
Strategic Opportunities	Combination therapies, new indications, digital engagement

---

6. Comparison with Key Market Alternatives

Criterion	Enstilar	Taclonex	Vtama	GENERIC TOPICALS
Formulation Type	Foam, corticosteroid + Vit D	Gel/Lotion, corticosteroid + Vit D	Ointment, steroid-free	Creams, ointments, foams
Indications	Psoriasis vulgaris, scalp	Psoriasis vulgaris, scalp	Plaque psoriasis	General psoriasis management
Approval Timeline	2016 (FDA), 2017 (EMA)	2006 (FDA & EMA)	2021	Varies
Market Penetration	Moderate	High in certain markets	Emerging	High

---

7. Regulatory and Policy Landscape

Region	Key Policies	Impact
US (FDA)	Expedited review pathways (e.g., Priority Review Act)	Faster access for innovative treatments
EU (EMA)	Orphan drug status, market exclusivity	Extends patent life, incentivizes innovation
Asia	Variable patent enforcement, varying approval processes	Growth depends on regional strategy
Price control policies	Stringent in some markets (e.g., India, parts of Europe)	Cap margins, influence revenue potential

---

Key Takeaways

• Enstilar's growth lies in regional expansion, indication diversification, and lifecycle management. The product benefits from a differentiated formulation and a strong foothold in the topical psoriasis segment.
• Pricing, patent expiration, and competition from generics remain key risks. Effective lifecycle strategies like new formulations or combination therapies are vital.
• Projected revenue growth of approximately 8.5% annually till 2030 reflects the product’s market stability and expansion potential, contingent upon regulatory and competitive factors.
• Investors should monitor patent expiry timelines (around 2027) and emerging competitors. Strategic licensing and innovation are critical to maintaining market share.
• Market expansion into emerging markets and new indications offer significant upside, especially as psoriasis prevalence and awareness grow globally.

---

FAQs

1. What are the primary growth drivers for Enstilar?
   Expansion into emerging markets, new indications such as pediatric psoriasis, formulation innovations, and strategic licensing agreements.

2. How does patent expiry impact Enstilar's market potential?
   Patent expiration around 2027 could allow generic competitors, pressuring prices and margins unless lifecycle management measures are implemented.

3. What is Enstilar’s competitive advantage over alternatives?
   Its innovative foam delivery system, combined with efficacy and convenience, helps it maintain a competitive edge, especially over traditional topical formulations.

4. How might regulatory changes influence Enstilar’s sales?
   Supportive policies, expedited approvals, and favorable reimbursement can boost sales; restrictive measures could slow growth.

5. What is the outlook for new formulations or indications?
   Potential exists for steroid-free or combination products targeting broader dermatological conditions, which could significantly increase market penetration.

---

Sources

[1] MarketsandMarkets, "Psoriasis therapeutics Market," 2022
[2] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for psoriasis," The Lancet, 2019
[3] LEO Pharma Annual Report, 2022